Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?

Affiliations

¹ Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, P.R. China.
² Tricision Biotherapeutic Inc., Zhuhai, P.R. China.
³ First Affiliated Hospital, China Medical University, Shenyang, P.R. China.
⁴ Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
⁵ Department of Immunology, Duke University Medical University Medical Center, Durham, NC.

Review

Ligong Lu et al. Hepatology. 2021 Jan.

. 2021 Jan;73(1):414-421.

doi: 10.1002/hep.31279.

¹ Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, P.R. China.
² Tricision Biotherapeutic Inc., Zhuhai, P.R. China.
³ First Affiliated Hospital, China Medical University, Shenyang, P.R. China.
⁴ Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
⁵ Department of Immunology, Duke University Medical University Medical Center, Durham, NC.

No abstract available

References

1. Finn OJ, Rammensee HG. Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: nothing new in spite of the name. Cold Spring Harb Perspect Biol 2018;10:a028829.
1. Vormehr M, Tureci O, Sahin U. Harnessing tumor mutations for truly individualized cancer vaccines. Annu Rev Med 2019;70:395-407.
1. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-645.
1. Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat Med 2019;25:1488-1499.
1. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015;348:803-808.